# Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

> **NCT02858908** · PHASE2 · COMPLETED · sponsor: **AMO Pharma Limited** · enrollment: 16 (actual)

## Conditions studied

- Myotonic Dystrophy 1

## Interventions

- **DRUG:** Tideglusib

## Key facts

- **NCT ID:** NCT02858908
- **Lead sponsor:** AMO Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-20
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858908, "Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02858908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*